
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics Inc. is positioned for growth due to its innovative CPP technology platform and promising lead product candidate, CTI-1601, aimed at treating Friedreich's ataxia. Forecasted sales for nomlabofusp are expected to begin at $6 million in 2026 and reach $356 million by 2030, reflecting significant revenue potential as the product moves closer to market readiness. Additionally, positive interim data revealing increased FXN levels and validated mitochondrial activity in animal models supports a robust risk/benefit profile that could enhance investor confidence leading up to regulatory milestones and commercial launch.
Bears say
Larimar Therapeutics Inc, as a development-stage biotechnology company, struggles with consistent profitability and faces uncertainty regarding its path to profitability, which poses a significant burden on its stock performance. Compounding these challenges, the FDA's rejection of buccal/skin FXN as a surrogate endpoint hampers the company's regulatory advancements and raises concerns about the long-term viability of its lead product candidate, CTI-1601. Additionally, the potential need for invasive cardiac biopsies and high orphan drug pricing could lead to further commercialization and financing challenges, adding to the negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares